A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A S
about
Model selection of generalized estimating equations with multiply imputed longitudinal data.Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States.Model selection in the weighted generalized estimating equations for longitudinal data with dropout.A Heterogeneous Growth Curve Model for Nonnormal Data.Comparison of Modern Methods for Analyzing Repeated Measures Data With Missing Values.Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.Conditional Monte Carlo randomization tests for regression models.If I didn't have HIV, I'd be dead now: illness narratives of drug users living with HIV/AIDS.Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.Update on didanosine.Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trialsInterpretable inference on the mixed effect model with the Box-Cox transformation.Quantification of CD4 responses to combined antiretroviral therapy over 5 years among HIV-infected children in Kinshasa, Democratic Republic of CongoInference of median difference based on the Box-Cox model in randomized clinical trials.Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.Trends in Racial/Ethnic Disparities Among Patients Living with HIV in Texas, 1996 to 2013.Mutator dynamics in fluctuating environments.
P2860
Q30663022-2B44A0DE-D117-403A-9A87-71EEEA98948EQ30771786-58B6AC92-D51D-49F5-9C2F-81957C9C9DA4Q31012281-ABADEACB-FDB9-4639-B667-E76A9CCDA60EQ31028424-997D22B3-4134-4251-B8E0-9CE8F079858BQ31035258-331C5A9E-5450-4CC2-8FC8-6DB1352891B1Q33910056-3FF2AC08-E838-41D0-AF00-789B5A2340E3Q33945366-D4FD7AD3-B63D-4FC8-B116-37E97CE477FFQ34022462-82217365-1B43-44A4-94C9-8BC4F438FE98Q34055828-BD18D3C3-B154-4AEC-A57C-BF9FDE0AA641Q34732899-25E56ED9-33D7-4018-BD2D-54C4A2BCDA35Q35207285-225A5733-AF49-481D-8E11-613AFEDC4654Q35629103-06F3839F-26AD-48C0-9358-13012998B72DQ38907556-FEF6E7C9-CD82-493D-961E-C5B150E4612DQ41381835-5B66AFF7-E040-4BBE-A9E0-0E4EBA44B70AQ41615215-E60845D1-1005-4FD0-9B78-CB44E1603333Q43759280-9CAC8453-757D-4AD5-8C2B-275F4B4DADC9Q47261493-DD06FF6A-1672-4177-99DA-364C4B2EDCBFQ52043835-F4D30BE5-449A-4135-A5A7-8DB5906C090A
P2860
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A S
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
A randomized, controlled, doub ...... DS Clinical Trial Group 193A S
@en
A randomized, controlled, doub ...... DS Clinical Trial Group 193A S
@nl
type
label
A randomized, controlled, doub ...... DS Clinical Trial Group 193A S
@en
A randomized, controlled, doub ...... DS Clinical Trial Group 193A S
@nl
prefLabel
A randomized, controlled, doub ...... DS Clinical Trial Group 193A S
@en
A randomized, controlled, doub ...... DS Clinical Trial Group 193A S
@nl
P2093
P1476
A randomized, controlled, doub ...... DS Clinical Trial Group 193A S
@en
P2093
Balfour HH Jr
Martinez A
P304
P356
10.1097/00042560-199812010-00004
P407
P577
1998-12-01T00:00:00Z